History & Overview

Algernon Pharmaceuticals is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).

The Algernon drug development program was the brainchild of Dr. Mark Williams, the Company’s CSO, whose innovative approach to drug discovery was developed over many years as senior scientist in the drug development industry. The company and its business model is highly capital efficient and strives to deliver maximum shareholder value.
Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

Drug Repurposing Strategy

A Drug Repurposing Strategy Can Save up to 8 years of Pre-Clinical Research And Multi Millions in R&D Costs.

The Algernon business model is to take safe approved genericized drugs, screen them in globally accepted animal models for new diseases, file new intellectual property rights and then efficiently move them into off label phase II trials in the country where they were originally approved. Once a signal is established in a human trial, the company will begin to advance the repurposed drug through a US FDA registration.

11 drug candidates were initially screened by the Company in globally accepted in vivo animal models for 4 new disease areas:

  • Non-alcoholic Steatohepatitis (NASH)
  • Chronic Kidney Disease (“CKD”)
  • Inflammatory Bowel Disease (IBD)
  • Idiopathic Pulmonary Fibrosis(IPF)

Initial studies showed that a number of the 11 drug candidates either performed equal to or better than the positive controls in each of the animal studies. Subsequent in vivo studies have confirmed their efficacy.

All Algernon research studies were conducted by 3rd party contract research organizations. The studies were well designed with proper positive controls, using the currently accepted gold standard for treatment in the disease being screened.

4
Phase II Clinical Trials Being Planned by Algernon
55 %
of Phase II trials Succeed*

*Source: PhRMA

33 %
of Successful Phase II Drugs Are Approved